Funding for this research was provided by:
The Axel Muusfeld Foundation
The Research Foundation of the Central Denmark Region
Received: 19 June 2022
Accepted: 5 October 2022
First Online: 28 November 2022
: FHM has received personal fees from Astra Zeneca. All other authors have no competing interests.
: The study was approved by the Regional Scientific Ethics Committee (journal number: 1-10-72-35-18), the Danish Medicines Agency (EudraCT-number: 2017-005008-88), the Danish Data Protection Agency, and was conducted in agreement with the Declaration of Helsinki 2013. Informed written consent was provided by all participating subjects.
: Informed consent was obtained from all participants regarding publishing of data.